No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial

In the ASPIRE trial, antiretroviral therapy (ART) switch to dolutegravir plus lamivudine (DTG+3TC) was comparable to 3-drug ART in maintaining viral suppression by standard viral load assays. We used an ultrasensitive assay to assess whether this switch led to increased residual viremia. At entry, l...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Open Forum Infect Dis
Auteurs principaux: Li, Jonathan Z, Sax, Paul E, Marconi, Vincent C, Fajnzylber, Jesse, Berzins, Baiba, Nyaku, Amesika N, Fichtenbaum, Carl J, Wilkin, Timothy, Benson, Constance A, Koletar, Susan L, Lorenzo-Redondo, Ramon, Taiwo, Babafemi O
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2019
Sujets:
Brief Report
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6419983/
https://ncbi.nlm.nih.gov/pubmed/30895201
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz056
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires